- £3.99bn
- £4.78bn
- $2.88bn
- 74
- 48
- 69
- 72
REG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Annual Financial Report
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Board Committee Changes
AnnouncementRCS - Hikma Pharmaceutical - Hikma enters agreement to commercialise Ryaltris™
AnnouncementREG - Hikma Pharmaceutical - Final Results
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementREG - Hikma Pharmaceutical - Notice of Results
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementRCS - Hikma Pharmaceutical - Hikma announces agreement with Chiesi Group
AnnouncementRCS - Hikma Pharmaceutical - Hikma announces agreement with Arecor
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementRCS - Hikma Pharmaceutical - Civica Rx and Hikma announce shipment of medicines
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementREG - Hikma Pharmaceutical - Hikma completes FDA response for generic Advair®
Announcement